Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 avr. 2018 03h10 HE | Source: Assembly Biosciences

Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference

Robust antiviral activity observed in HBV patients Generally safe and well tolerated Planning underway for Phase 2a studies beginning summer 2018 Company to host conference call on Thursday, April...
10 avr. 2018 17h40 HE | Source: Assembly Biosciences

Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL

INDIANAPOLIS and SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the...
02 avr. 2018 16h54 HE | Source: Assembly Biosciences

Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome

INDIANAPOLIS and SAN FRANCISCO, April 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the...
28 mars 2018 05h30 HE | Source: Assembly Biosciences

Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL)

INDIANAPOLIS and SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the...
12 mars 2018 07h05 HE | Source: Assembly Biosciences

Assembly Biosciences Announces Additions to Management Team and Board of Directors

INDIANAPOLIS, March 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
05 mars 2018 07h00 HE | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference

INDIANAPOLIS, March 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
05 févr. 2018 07h05 HE | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference

INDIANAPOLIS, , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
02 févr. 2018 16h30 HE | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

INDIANAPOLIS, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
04 janv. 2018 07h05 HE | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present at the J.P. Morgan Healthcare Conference

INDIANAPOLIS, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
18 déc. 2017 16h05 HE | Source: Assembly Biosciences, Inc.

Assembly Biosciences Appoints Sue Mahony, PhD to Board of Directors

INDIANAPOLIS, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...

Page précédente